Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast
Keywords:
Breast neoplasms, Ductal carcinoma in situ, Carcinoma, Receptor erbB-2, Protein p53Abstract
CONTEXT AND OBJECTIVE: Breast cancer is thought to derive from progressively aberrant, non-invasive breast lesions, but it is not known exactly how invasive breast cancer develops from these lesions. The aim of this study was to verify the changes in c-erbB-2 and p53 protein expression between non-neoplastic ducts, ductal carcinoma in situ and invasive ductal carcinoma found in the same breast. DESIGN AND SETTING: This was a cross- sectional study at Centro de Atenção Integral à Saúde da Mulher, Campinas, Brazil. METHODS: Fifty-six women with invasive ductal carcinoma and ductal carcinoma in situ in the same breast were included. The expression of c-erbB-2 and p53 proteins was assessed in non-neoplastic and neoplastic cells using im- munohistochemical techniques. RESULTS: The c-erbB-2 protein was absent in non-neoplastic ducts but was present in 46% and 36% of in situ and invasive carcinoma compo- nents, respectively. Only 2% of non-neoplastic ducts, and 18% and 16% of ductal carcinoma in situ and invasive carcinoma components, respectively, were positive for p53 protein. No significant difference in c-erbB-2 and p53 protein expression was observed between in situ and invasive components. The nuclear grade agree- ment between in situ and invasive carcinoma was very good. CONCLUSIONS: The invasiveness of ductal carcinoma in situ seems to be independent of the Her-2/neu and TP53 genes. The general features of an occurrence of breast carcinoma are formulated at the outset of carcinogenesis, and the Her-2/neu and TP53 genes are involved.
Downloads
References
Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol. 2002;196(3):280-6.
Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430-41.
Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol. 2000;9(1):14-9.
Mommers EC, Leonhart AM, Falix F, et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol. 2001;194(3):327-33.
Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer. 2001;85(6):869-74.
Goldstein NS, Murphy T. Intraductal carcinoma associated with invasive carcinoma of the breast. A comparison of the two lesions with implications for intraductal carcinoma classification systems. Am J Clin Pathol. 1996;106(3):312-8.
Consensus Conference on the classification of ductal carci- noma in situ. The Consensus Conference Committee. Cancer. 1997;80(9):1798-802.
Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991.
De Potter CR, Van Daelle S, Van de Vijver MJ, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology. 1989;15(4):351-62.
Umekita Y, Takasaki T, Yoshida H. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immuno- histochemical study. Virchows Arch. 1994;424(5):491-4.
Allred DC, Clark GM, Molina R, et al. Overexpression of HER- 2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23(9):974-9.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68.
Aubele M, Werner M, Höfler H. Genetic alterations in presump- tive precursor lesions of breast carcinomas. Anal Cell Pathol. 2002;24(2-3):69-76.
Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8(1):47-61.
Coene ED, Schelfhout V, Winkler RA, et al. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virchows Arch. 1997;430(5):365-72.
Heffelfinger SC, Yassin R, Miller MA, Lower EE. Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breast pathologies: correlation with vascularity. Pathobiology. 2000;68(3):129-36.
Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992;16(12):1133-43.
Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in hu- man breast cancer and its clinical significance. Eur J Cancer. 1998;34(6):791-808.
Warnberg F, Casalini P, Nordgren H, Bergkvist L, Holmberg L, Menard S. Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis. Breast Cancer Res Treat. 2002;73(3):215-21.
Alexiev BA, Bassarova AV, Popovska SL, Popov AA, Christov CZ. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index. Gen Diagn Pathol. 1997;142(5-6):271-9.
Viacava P, Naccarato AG, Bevilacqua G. Different proliferative patterns characterize different preinvasive breast lesions. J Pathol. 1999;188(3):245-51.
Giardina C, Serio G, Lepore G, et al. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study. J Exp Clin Cancer Res. 2003;22(2):279-88.
Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1(5):362-75.
Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974-9.
